Close

Share this page

South Korea

Established in 2011, EPS International Korea Limited strengthens EPSI's capabilities by offering CRO services involving multinational clinical studies centered in Asia and involving multiple territories in the region. The company reinforces clinical trials that require advanced technology, enjoying support from the Korean government on drug registration, and leveraging the emergence of the country as a choice location for conducting clinical research.


Fast Facts

Health Expenditure per Capita
(2014, US$)

$2060

Source: World Health Organization Global Health Expenditure Database

Life Expectancy at Birth
(2016 est.)

male

79

years

female

85

years

Source: The World Fact Book;
Central Intelligence Agency

Burden of Disease DALYs Causes % of Total DALYs
(2015, all ages/both sexes)

Low back and neck pain (7.02%)

Cerebrovascular disease (5.83%)

Diabetes mellitus (4.98%)

Source: Global Burden of Disease Study 2015;
Institute for Health Metrics and Evaluation

NDA Approval Time

3

months




Features

Vigorous investment in drug development and biosimilars in Korea are creating a global powerhouse

Strategic investment and targeted policy is transforming Korea's pharmaceutical industry, as it moves away from generics towards biosimilars and drug development. Previously known for a conservative approach, Korea is now poised ...

Korea is rapidly becoming a regional leader in clinical trials

Although a latecomer to clinical research, CRO activity in South Korea has grown rapidly since its origin in 1995. Particularly, since 2007, with the establishment of Korean National Enterprise for Clinical Trials (KoNECT) within the Ministry of ...


Services Available in South Korea

Seoul Office

13 Fl. Songgang Bldg., 15, Teheran-ro 98-gil, Gangnam-gu, Seoul 135-846, South Korea
Tel: +82 70 4640 6839
Fax: +82 70 8220 6866
E-mail: sales@epsi-global.com


We will tailor an ideal solution for your specific needs.

Request a Proposal